Antibody Aggregation: Insights from Sequence and Structure
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important applications ranging from cancers, autoimmunity diseases and metabolic disorders to emerging infectious diseases. Aggregation of mAbs continues to be a major problem in their developability. Antibody aggregation could be triggered by partial unfolding of its domains, leading to monomer-monomer association followed by nucleation and growth. Although the aggregation propensities of antibodies and antibody-based proteins can be affected by the external experimental conditions, they are strongly dependent on the intrinsic antibody properties as determined by their sequences and structures. In this review, we describe how the unfolding and aggregation susceptibilities of IgG could be related to their cognate sequences and structures. The impact of antibody domain structures on thermostability and aggregation propensities, and effective strategies to reduce aggregation are discussed. Finally, the aggregation of antibody-drug conjugates (ADCs) as related to their sequence/structure, linker payload, conjugation chemistry and drug-antibody ratio (DAR) is reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“For example, many proteins involved in hereditary forms of protein deposition diseases bear mutations decreasing the conformational stability of the folded monomer and promote aggregation in vitro [38,41,42].”
BackgroundProtein folding and misfolding
Dobson, C. M. (2003) · Nature · doi:10.1038/nature02261 · Cited by 4,791
PatchDock and SymmDock: servers for rigid and symmetric docking
Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., & Wolfson, H. J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki481 · Cited by 3,018 · cited 1×
“The fact that the higher DAR could pose more structural alterations is further supported by our molecular docking (PatchDock simulations [136]) studies of m860-MMAF and m900-MMAE with different DARs.”
ResultHow fast-folding proteins fold
Lindorff-Larsen, K., Piana, S., Dror, R. O., & Shaw, D. E. (2011) · Science · doi:10.1126/science.1208351 · Cited by 1,980
Natural β-sheet proteins use negative design to avoid edge-to-edge aggregation
Richardson, J. S., & Richardson, D. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052706099 · Cited by 753 · cited 2×
“Antibodies either inwardly point a charged residue in the middle of the β strand to disfavor the hydrophobic associations or they locate a proline to introduce a bulge dissecting the strand to avoid edge-edge association [16].”
BackgroundStability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Conformational diversity and protein evolution – a 60-year-old hypothesis revisited
James, L. C., & Tawfik, D. S. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00135-x · Cited by 579 · cited 1×
“Proteins experience constant sampling between the folded and partially-folded structures [4].”
BackgroundTherapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350 · cited 1×
“Furthermore, antibody aggregation is highly undesirable, because it could compromise biological functions [12], induce immune responses by breaking B-cell tolerance [23,24] and evoke antibody clearance machinery in vivo [25].”
BackgroundA strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Cited by
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Kenaan, A., Li, K., Barth, I., Johnson, S., Song, J., & Krauss, T. F. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112047 · Cited by 61
Lai, P.-K., Fernando, A., Cloutier, T. K., Kingsbury, J. S., Gokarn, Y., Halloran, K. T., Calero-Rubio, C., & Trout, B. L. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.014 · Cited by 45
Lee, A. P., Kok, Y. J., Lakshmanan, M., Leong, D., Zheng, L., Lim, H. L., Chen, S., Mak, S. Y., Ang, K. S., Templeton, N., et al. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27899 · Cited by 40
“ER and oxidative stress are also known to exacerbate each other (Nakka et al., 2016), and their resultant disruption of ER homeostasis promotes accumulation of unfolded proteins which can lead to aggregation of mAb into HMW species (Li et al., 2016; Zhou et al., 2018).”
Background
Metadata
- Authors
- Li, W., Prabakaran, P., Chen, W., Zhu, Z., Feng, Y., & Dimitrov, D.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2016-09-05
- Volume
- 5
- Issue
- 3
- Pages
- 19
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W2508555854
- Cited by
- 149
- References
- 12
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibody Aggregation: Insights from Sequence and Structure. https://app.cochat.ai/papers/10.3390/antib5030019
- The paper
- Li, W., Prabakaran, P., Chen, W., Zhu, Z., Feng, Y., & Dimitrov, D. (2016). Antibody Aggregation: Insights from Sequence and Structure. Antibodies. https://doi.org/10.3390/antib5030019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.